Tags

Type your tag names separated by a space and hit enter

Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
Diagn Microbiol Infect Dis. 2004 Aug; 49(4):273-81.DM

Abstract

The U.S. Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme in the fifth year continues to monitor the spectrum of activity and potency of meropenem within medical centers where carbapenems are used for the treatment of serious infections. The antimicrobial activity of 11 broad-spectrum agents (including initial comparisons for levofloxacin) was assessed against 2,848 isolates in 2003. The minimum inhibitory concentration (MIC) results demonstrate the continued high potency of meropenem against all monitored pathogens. Against all Gram-negative bacilli tested, the overall rank order of susceptibility was meropenem (96.3%) > imipenem (95.6%) > cefepime (93.7%) > tobramycin (91.9%) > piperacillin/tazobactam (90.2%) > ceftazidime (90.1%) > gentamicin (89.6%) > levofloxacin (82.8%) > ciprofloxacin (82.5%) > aztreonam (81.8%) > ceftriaxone (72.3%). Clonal-based resistances were observed that adversely influenced carbapenem resistance rates, particularly among Klebsiella spp. and Acinetobacter baumannii isolates. Continued surveillance of the carbapenem class and other broad-spectrum agents is warranted to monitor activity against pathogens causing serious infections in hospitalized patients.

Authors+Show Affiliations

The Jones Group/JMI Laboratories, North Liberty, IA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15313533

Citation

Rhomberg, Paul R., et al. "Antimicrobial Resistance Rates and Clonality Results From the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of Year Five (2003)." Diagnostic Microbiology and Infectious Disease, vol. 49, no. 4, 2004, pp. 273-81.
Rhomberg PR, Jones RN, Sader HS, et al. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). Diagn Microbiol Infect Dis. 2004;49(4):273-81.
Rhomberg, P. R., Jones, R. N., Sader, H. S., & Fritsche, T. R. (2004). Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). Diagnostic Microbiology and Infectious Disease, 49(4), 273-81.
Rhomberg PR, et al. Antimicrobial Resistance Rates and Clonality Results From the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of Year Five (2003). Diagn Microbiol Infect Dis. 2004;49(4):273-81. PubMed PMID: 15313533.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). AU - Rhomberg,Paul R, AU - Jones,Ronald N, AU - Sader,Helio S, AU - Fritsche,Thomas R, AU - ,, PY - 2003/12/10/received PY - 2004/02/10/accepted PY - 2004/8/18/pubmed PY - 2004/10/22/medline PY - 2004/8/18/entrez SP - 273 EP - 81 JF - Diagnostic microbiology and infectious disease JO - Diagn. Microbiol. Infect. Dis. VL - 49 IS - 4 N2 - The U.S. Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme in the fifth year continues to monitor the spectrum of activity and potency of meropenem within medical centers where carbapenems are used for the treatment of serious infections. The antimicrobial activity of 11 broad-spectrum agents (including initial comparisons for levofloxacin) was assessed against 2,848 isolates in 2003. The minimum inhibitory concentration (MIC) results demonstrate the continued high potency of meropenem against all monitored pathogens. Against all Gram-negative bacilli tested, the overall rank order of susceptibility was meropenem (96.3%) > imipenem (95.6%) > cefepime (93.7%) > tobramycin (91.9%) > piperacillin/tazobactam (90.2%) > ceftazidime (90.1%) > gentamicin (89.6%) > levofloxacin (82.8%) > ciprofloxacin (82.5%) > aztreonam (81.8%) > ceftriaxone (72.3%). Clonal-based resistances were observed that adversely influenced carbapenem resistance rates, particularly among Klebsiella spp. and Acinetobacter baumannii isolates. Continued surveillance of the carbapenem class and other broad-spectrum agents is warranted to monitor activity against pathogens causing serious infections in hospitalized patients. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/15313533/Antimicrobial_resistance_rates_and_clonality_results_from_the_Meropenem_Yearly_Susceptibility_Test_Information_Collection__MYSTIC__programme:_report_of_year_five__2003__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732889304000306 DB - PRIME DP - Unbound Medicine ER -